Date post: | 27-Dec-2015 |
Category: |
Documents |
Upload: | meredith-jefferson |
View: | 214 times |
Download: | 0 times |
Three key messages on tuberculosis control
World Tuberculosis Day 2010
ECDC TB TeamEuropean Centre for Disease Prevention and ControlStockholm, 24 March 2010
1a. The treatment success rate in the EU/EEA is too low to meet global targetsReported treatment success rates in the EU/EEA are far below the 85% target set by the WHO World Health Assembly. Only three EU/EEA countries recorded a treatment success rate over 85% or more for new laboratory-confirmed pulmonary TB cases.
* Treatment success rate among not previously diagnosed cases. Source: ECDC
85% target set by the Stop TB Partnership.
Only Iceland, Portugal and Slovakia meet the 85% target.
Figure 1a: Treatment success rate among new laboratory-confirmed pulmonary TB cases, 2007
0102030405060708090
100
% Tre
atm
ent
succ
ess
rate
1b. The treatment success rate in the EU/EEA is too low to meet global targetsFigure 1b: Percentage success rate among laboratory-confirmed new pulmonary TB cases, EU/EEA, 2007
71 to 84%
≥ 85%
60 to 70%
< 60%
Not included or not reporting
Source: ECDC
1c. The treatment success rate in the EU/EEA is too low to meet global targetsTreatment success among previously untreated laboratory-confirmed pulmonary TB remains low in the EU/EEA and is below the 85% target. No changes in the trend were seen in the last five years. Figure 1c: EU/EEA treatment outcome among laboratory-confirmed pulmonary cases 2003–2007
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
100.00
2003 2004 2005 2006 2007 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
* Excluded: Austria, Bulgaria, Finland, France, Greece, Liechtenstein, Luxembourg, and Spain
Previously untreated Previously treated All pulmonary cases
Success
Died
Failed
Defaulted
Still on treatment
Transferred or unknown
* Excluded: Austria, Bulgaria, Cyprus, Finland, France, Greece, Italy, Liechtenstein and Spain
100
90
80
70
60
50
40
30
20
10
0
2a. MDR TB* remains a problem in the EU/EEAFigure 2a: Proportion of notified TB cases with primary multidrug resistance, EU/EEA, 2008
2 to 5.9%
> 10%
1 to 1.9%
> 6-10%
< 1%
Not included or not reporting
* Multidrug-resistant tuberculosis (MDR TB) is defined as TB that is resistant at least to isoniazid (INH) and rifampicin (RMP), the two most powerful first-line anti-TB drugs.
2b. MDR TB remains a problem in the EU/EEA Treatment success rate among MDR TB cases is extremely low (31%).
78%
31%
7%
17%
3%
17%
6%
13%
2%
17%
5% 5%
0
10
20
30
40
50
60
70
80
90
MDR MDR MDR MDR MDR MDR
Success Died Failed Defaulted Still on treatment
Transferred or unknown
Figure 2b: Treatment outcome of all* MDR TB cases, compared to all non-MDR cases, EU/EEA, 2006**
* Pulmonary and extra-pulmonary ** Both groups are 2006 treatment cohorts
Non-MDR Non-MDR Non-MDR Non-MDR Non-MDRNon-MDR
3a. The decline in tuberculosis has levelled off in the EU/EEA
Figure 3a: TB notification rates by incidence grouping, 1995–2008 and 2002–2008
Source: ECDC
The decrease in TB notification rates has stagnated in the EU/EEA.
The decline seen in countries with high and intermediate incidence rates contributes substantially to the average EU/EEA decline.
<20/100 000
EU/EEA
>20/100 000
Noti
fica
tion r
ate
(per
100
00
0 p
opula
tion)
3b. The decline in tuberculosis has levelled off in the EU/EEA
0
5
10
15
20
25
19951996199719981999200020012002200320042005200620072008
19951996
19971998
1999
2000
25
20
15
10
5
0
20012002
20032004
20052006
20072008
Notification rate (per 100 000 population)
Figure 3b: TB notification rates, 1995–2008, EU/EEA